newwin
Luciann Nguyen
Settings
← Accounts
biotech

Centre Leon Berard

61
Account opportunity
Not established
Relationship
2
Active signals
2
Trials as sponsor

Why this account matters

61/100
Opportunity
Commercial fit12/25
Clinical timing20/20
Biomarker need10/20
Relationship2/10
Signal strength9/10
Account value7/10
Urgency1/5

New phase 2 trial NCT02029001 posted by Centre Leon Berard: "Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment". New trial on a phase 2 recruiting study is a moment when external vendors are commonly selected or expanded (spec §70).

Why nowClinicalTrials.gov record updated 41 days ago.

ConfidenceHigh · 95%clinical development · translational medicine · clinical operations

NextMap clinical development and translational medicine stakeholders on the sponsor, confirm no colleague is mid-conversation, then draft evidence-based outreach.

55/100
Opportunity
Commercial fit11/25
Clinical timing20/20
Biomarker need5/20
Relationship2/10
Signal strength9/10
Account value7/10
Urgency1/5

New phase 2 trial NCT04116541 posted by Centre Leon Berard: "A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.". New trial on a phase 2 recruiting study is a moment when external vendors are commonly selected or expanded (spec §70).

Why nowClinicalTrials.gov record updated 62 days ago.

ConfidenceHigh · 87%clinical development · translational medicine · clinical operations

NextMap clinical development and translational medicine stakeholders on the sponsor, confirm no colleague is mid-conversation, then draft evidence-based outreach.

Trials

TrialPhaseTesting language
NCT02029001
Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment
phase 2
ctDNA
NCT04116541
A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.
phase 2
mol. elig.